3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Breast Neoplasms
10
Pain, Postoperative
9
Neoplasms
9
Parkinson Disease 4, Autosomal Dominant Lewy Body
8
Lung Neoplasms
8
Stomach Neoplasms
6
Colonic Neoplasms
6
Brain Neoplasms
6
Thyroid Neoplasms
5
Prostatic Neoplasms
5
Colorectal Neoplasms
5
Agnosia
4
Thromboembolism
3
Pain
3
Ovarian Neoplasms
3
Myofibroma
3
Head and Neck Neoplasms
3
Depression
3
Carcinoma, Non-Small-Cell Lung
3
Carcinoma, Hepatocellular
3
Uterine Neoplasms
2
Urinary Bladder Neoplasms
2
Supratentorial Neoplasms
2
Neoplasm Metastasis
2
Leiomyoma
2
Hemangioma
2
Arthritis, Rheumatoid
2
Vomiting
1
Visceral Pain
1
Uterine Cervical Neoplasms
1
Interventions
Carboplatin
49
Etoposide
46
Cisplatin
42
Topotecan
39
Irinotecan
21
Paclitaxel
20
Nivolumab
15
pembrolizumab
13
Gemcitabine
13
atezolizumab
11
Ipilimumab
11
durvalumab
9
Radiotherapy
9
Doxorubicin
7
Bevacizumab
7
rovalpituzumab tesirine
6
etoposide phosphate
6
amrubicin
6
Psychiatric Rehabilitation
6
PM 01183
6
Docetaxel
6
Counseling
6
trilaciclib
5
Temozolomide
5
Sunitinib
5
Platinum
5
Imatinib Mesylate
5
Cyclophosphamide
5
Bortezomib
5
130-nm albumin-bound paclitaxel
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Small Cell Lung Carcinoma
×
Saline Solution
×
Clear all
NCT03066778
2022-10-03
KEYNOTE-604
Merck Sharp & Dohme LLC
Phase 3
Completed
453 enrolled
23 charts